Patents by Inventor Irving L. Weissman

Irving L. Weissman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTORS AND CELLS THAT PROVIDE FOR INDUCTION OF BONE, BONE MARROW, AND CARTILAGE
    Publication number: 20170360838
    Abstract: Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo.
    Type: Application
    Filed: January 6, 2016
    Publication date: December 21, 2017
    Inventors: Charles K.F. Chan, Irving L. Weissman, Michael T. Longaker
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20170362332
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 21, 2017
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • LONG TERM HEMATOPOIETIC STEM CELL SPECIFIC REPORTER MOUSE AND USES THEREOF
    Publication number: 20170350879
    Abstract: Hoxb5 identifies long-term hematopoietic stem cells. Expression of Hoxb5 distinguishes between LT-HSCs and non-LT-HSCs, and the marker identifies substantially all LT-HSC in the bone marrow. By utilizing fluorescent proteins under the endogenous expression control of Hoxb5, LT-HSC can be monitored and isolated, including without limitation detection and monitoring of HSC in bone morrow; production of LT-HSC from pluripotent stem cells such as iPS cells; for analysis of early stage LT-HSC; in screening methods for expansion and manipulation of LT-HSC, and the like.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Inventors: James Y. Chen, Masanori Miyanishi, Irving L. Weissman
  • Methods for Manipulating Phagocytosis Mediated by CD47
    Publication number: 20170320945
    Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 9, 2017
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • PERICYTES ARE INTERMEDIATE PROGENITORS FOR EPICARDIAL DERIVED CORONARY ARTERY SMOOTH MUSCLE
    Publication number: 20170312319
    Abstract: Methods and compositions are provided for regenerating smooth muscle tissue by the provision of a purified population of epicardial-derived pericytes, where the smooth muscle tissue may comprise, without limitation, coronary artery tissue; kidney tissue, etc. Compositions and kits for practicing the methods and/or for use with the systems of the disclosure are also provided.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Inventors: Kristy Red-Horse, Katharina Volz, Irving L. Weissman
  • METHODS FOR DETERMINING RESPONSIVENESS TO AN ANTI-CD47 AGENT
    Publication number: 20170306413
    Abstract: Methods and kits are provided for determining whether an individual is responsive to an anti-CD47 agent by assaying biological samples for the level or ratio of isoforms of CD47 in the sample.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 26, 2017
    Inventors: Irving L. Weissman, Victor Albert Eng, Rahul Sinha
  • Markers of acute myeloid leukemia stem cells
    Patent number: 9796781
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: October 24, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman
  • TARGETING ANEURYSM DISEASE BY MODULATING PHAGOCYTOSIS PATHWAYS
    Publication number: 20170291945
    Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 12, 2017
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 9771428
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 26, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman
  • Methods for manipulating phagocytosis mediated by CD47
    Patent number: 9765143
    Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 19, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
    Publication number: 20170233451
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Application
    Filed: August 7, 2015
    Publication date: August 17, 2017
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • ENGRAFTMENT OF STEM CELLS WITH A COMBINATION OF AN AGENT THAT TARGETS STEM CELLS AND MODULATION OF IMMUNOREGULATORY SIGNALING
    Publication number: 20170224737
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 10, 2017
    Inventors: Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr
  • TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS
    Publication number: 20170210803
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 27, 2017
    Inventors: Stephen Willingham, Doris Po Yi Ho, Kelly Marie McKenna, Irving L. Weissman, Jens-Peter Volkmer, Mark P. Chao, Ravindra Majeti, Melissa N. McCracken
  • Methods for Manipulating Phagocytosis Mediated by CD47
    Publication number: 20170190776
    Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 6, 2017
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • TREATMENT OF CANCER WITH DUAL TARGETING OF CD47 AND EGFR
    Publication number: 20170166645
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 15, 2017
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • MACROPHAGE OR MONOCYTE ENHANCED WOUND HEALING
    Publication number: 20170157296
    Abstract: Compositions and methods are provided for enhanced healing of wounds, e.g. cutaneous wounds, by application of a scaffold or matrix, e.g. a hydrogel film comprising a dose of macrophages, or monocyte progenitors thereof, which dose is effective in increasing the rate of wound healing. The compositions of the invention find use in treating cutaneous wounds, particularly chronic wounds, e.g. in diabetic patients or other patients with impaired wound healing.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 8, 2017
    Inventors: Graham G. Walmsley, Kipp Andrew Weiskopf, Michael Sung-Min Hu, Michael T. Longaker, Irving L. Weissman, Geoffrey C. Gurtner, Jayakumar Rajadas
  • METHODS FOR ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS
    Publication number: 20170145096
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Methods of manipulating phagocytosis mediated by CD47
    Patent number: 9624305
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 18, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
    Patent number: 9623079
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: April 18, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • Methods of manipulating phagocytosis mediated by CD47
    Patent number: 9611329
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 4, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao